The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The approval is backed by data showing deep, durable responses and manageable tolerability
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Subscribe To Our Newsletter & Stay Updated
